Drug Testing in Hematological Cancers

Diag2Tec is a preclinical CRO devoted to Hematological Malignancies, especially Multiple Myeloma (MM).

We focused on in vitro Drug Testing in Human Hematological Cancer derived Cell Lines and Primary Cells from patients with various Hematologic Malignancies. With our Drug Testing Services and ChimioFx Platforms, our mission is to provide efficient treatment solutions for patients suffering from Hematological Malignancies with Precision Medicine approaches. We support biotech and phamaceutical companies to focus their drug development on the right molecules in the right indications.


Unique Collection of 40 Human Myeloma Cell Lines

  • Representative of the molecular and clinical heterogeneity of multiple myeloma: subgroups, subclones and mutations and drug resistance found in patients.
  • Characterized at different molecular levels (Gene Expression Profiling, RNA seq, Exome seq, SNP, ChiP seq, miR, DNA methylation).
  • Profile of response to treatment using 20 molecules: IC50s.
  • Development of resistant cell lines to conventional treatments.

Read more


Primary Human
Multiple Myeloma Cells

  • Access to a bank of primary MM cells: at diagnosis or relapse.
  • Strong expertise in the culture and the identification of different cell subpopulations.
  • Access to clinical responses, serum, DNA and RNA of tumoral cells.
  • Access to gene expression profiling and exome of purified tumoral cells.

Read more


Other Hematological

  • Collection of Diffuse Large B-cell Lymphoma (DLBCLs) and Acute Myeloid Leukemia (AML) cell lines to offer you our wide range of services.
  • We have also access to a bank of primary cells from patients with various hematological malignancies: DLBCL, AML, Mantle Cell Lymphoma, Chronic Lymphoid Leukemia ect… (contact us for more information).

Read more



  • Profiling of cell lines after treatment by a specific therapeutic agent (RNA seq, mutations, histones mark…).
  • Exploring the mechanisms by which resistance/sensitivity modifications are related to specific investigated agent.

Read more



  • Identification of new therapeutic targets.
  • Identification of prognosis biomarkers.
  • Identification of biomarkers to predict the sensitivity/resistance of cancer cells to a given drug.
  • Investigation of the genomic expression of your targets in normal and cancer cell from cohorts of patients with hematological malignancies.

Read more

Drug Testing Services in Hematological Cancers:

Based on our different models and expertise to access the Efficacy and the Mechanism of Action of various Anticancer Drugs including Targeted, Chemotherapies and Immunotherapies alone or in combination, Diag2Tec offers to pharmaceutical laboratories, biotechnology companies, CRO or academic laboratories, a large selection of preclinical services:

In addition, Diag2Tec can also offer you other customized services based on your unique needs.

Contact us for more information

Why Choose Us?

  • Our Expertise > 30 years in the Biology of Multiple Myeloma.
  • Our Unique Collection of 40 Human Myeloma Cells Lines and Resistant Cell Lines.
  • Drug Testing in Primary Human cells from Patients with various Hematological Malignancies (Genomic and Clinical informations).
  • Innovative Biomathematical Models Patented for Predictive Biomarkers Identification.
  • Tailored Studies Designed to Meet your Specific Needs.
  • Short Turnaround Times for Prompt and Cost Effective Molecule Investigation.

Diag2Tec’s Headquarters

Cap Omega, Rond-Point Benjamin Franklin
CS 39521
34960 Montpellier, France
Email: contact@diag2tec.com